Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Inhibition of [3H]-8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active | ChEMBL. | 10636243 | |
Activity (binding) | Inhibition of binding of [3H]-quinuclidinyl benzilate to Muscarinic acetylcholine receptor M2 in rat heart atria at 10e-5 M of compound concentrationLess active | ChEMBL. | 10636243 | |
Activity (binding) | Inhibition of binding of [3H]-quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in rat brain cortex at 10e-5 M of compound concentration;Less active | ChEMBL. | 10636243 | |
Activity (binding) | Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active | ChEMBL. | 10636243 | |
Activity (binding) | 0 | Inhibition of [3H]-8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active | ChEMBL. | 10636243 |
Activity (binding) | 0 | Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active | ChEMBL. | 10636243 |
Activity (binding) | 0 | Inhibition of binding of [3H]-quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in rat brain cortex at 10e-5 M of compound concentration;Less active | ChEMBL. | 10636243 |
Activity (binding) | 0 | Inhibition of binding of [3H]-quinuclidinyl benzilate to Muscarinic acetylcholine receptor M2 in rat heart atria at 10e-5 M of compound concentrationLess active | ChEMBL. | 10636243 |
Activity (binding) | 0 | Inhibition of binding of [3H]-nicotine to neural nicotinic cholinergic receptor in rat brain membranes at 10e-5 M of compound concentration; Less active | ChEMBL. | 10636243 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.